ECORHealthcare · Medical DevicesThe 5 Wall Street analysts covering electroCore, Inc. hold a median 12-month price target of $20 — +164.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 50 of 100 as at 31 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores electroCore, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (84): The shares have been drifting up relative to others.
Issuance (8): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on ECOR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +164.0% from it.
Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | $25 → $18 |
| 26 Jan 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 13 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Mar 2025 | Ladenburg Thalmann | Maintains | Buy | — |
| 18 Dec 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 14 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 Jan 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Nov 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Aug 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 May 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Apr 2023 | CG Capital | Reiterates | Outperform | — |
| 18 Apr 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Mar 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Jan 2023 | Brookline Capital | Initiates | Buy | $1.25 |
| 19 Jan 2022 | HC Wainwright & Co. | Maintains | Buy | $3.00 → $2.75 |
| 27 July 2021 | Ladenburg Thalmann | Initiates | Buy | — |
| 23 Oct 2020 | Brookline Capital | Initiates | Buy | — |
| 30 Sept 2020 | Maxim Group | Initiates | Buy | — |
| 14 Aug 2020 | BTIG | Upgrade | Buy | — |
| 14 Aug 2020 | HC Wainwright & Co. | Maintains | Buy | $2.50 → $3.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ECOR appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, electroCore, Inc. returned +54.1% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 52% of US stocks
Cheaper than 99% of US stocks
Cheaper than 81% of US stocks
Higher than 77% of US stocks
Higher than 65% of US stocks
Higher than 95% of US stocks
Higher than 19% of US stocks
Higher than 12% of US stocks
Higher than 99% of US stocks
Higher than 7% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
electroCore, Inc. has a market value of $73.1M and an enterprise value of $72.6M.
Revenue in the twelve months to 30 June 2026: $37.0M. The latest quarter grew 28.0% year on year.
Net income over the same four quarters: −$14.8M, a −40.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$9.7M.
Trailing P/E: −4.8×; forward P/E: −14.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
electroCore, Inc. employs 83 people — $445K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own electroCore, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
electroCore announced it will report its financial results for the third quarter ended September 30, 2026, after the market closes on Wednesday, November 4, 2026.
Why it matters — ECOR watchers can note the scheduled date when the company plans to release its quarterly results.
electroCore co-CEO, president and CFO Joshua Lev said the company aims to broaden its federal-market presence, expand product indications and reach adjusted EBITDA profitability in the second half of 2027.
Why it matters — The stated plans and profitability target provide ECOR watchers with an update on the company’s strategic priorities and financial goal.
electroCore submitted a 510(k) premarket notification to the FDA seeking clearance for its Quell wearable neuromodulation platform to treat chronic chemotherapy-induced peripheral neuropathy (CIPN).
Why it matters — The submission concerns a potential additional use for electroCore’s Quell platform, subject to FDA clearance.
electroCore announced that the U.S. Air Force Research Laboratory presented findings from a controlled fMRI study evaluating tcVNS during complex visual skill learning. The headline says the study suggests tcVNS accelerates neural processes in visual skill learning.
Why it matters — The announcement concerns research on tcVNS, a technology relevant to electroCore, but the excerpt provides no further study details.
electroCore announced that it will present at Planet MicroCap Toronto 2026 Powered by MicroCapClub, held at the Arcadian Court & Loft.
Why it matters — ECOR watchers may note the company's planned presentation at this event.
The 5 Wall Street analysts covering electroCore, Inc. have a median 12-month price target of $20, with estimates ranging from $12 to $26. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 5 analysts covering electroCore, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks electroCore, Inc. 50 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, electroCore, Inc. ranks 50 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (84 of 100).
No one can know that. What the data says: the median 12-month target from 5 analysts implies +164.0% from the last close, and Ticker Nerd's factor model ranks electroCore, Inc. 50 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering electroCore, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ECOR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $26 over the next 12 months.
electroCore, Inc. returned +54.1% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
electroCore, Inc. is a commercial-stage bioelectronic medicine company that develops non-invasive vagus nerve stimulation (nVNS) products for healthcare and wellness use.
The most recent item we track (GlobeNewsWire, 29 Oct 2026): "electroCore to Announce Third Quarter September 30, 2026, Financial Results on Wednesday, November 4, 2026". electroCore announced it will report its financial results for the third quarter ended September 30, 2026, after the market closes on Wednesday, November 4, 2026.
electroCore, Inc. is a commercial-stage bioelectronic medicine company that develops non-invasive vagus nerve stimulation (nVNS) products for healthcare and wellness use. Its core offerings include gammaCore, a prescription handheld device used for primary headache conditions such as migraine and cluster headache, as well as Quell Fibromyalgia for chronic pain management. The company also markets Truvaga and TAC-STIM, consumer-focused nVNS products designed to support general wellness and human performance. electroCore’s technology platform is built around non-invasive neuromodulation, with products intended for both clinical and personal use across the United States, the United Kingdom, and international markets. Headquartered in Rockaway, New Jersey, electroCore serves a growing role in the medical device and bioelectronic therapy sectors by offering portable, non-surgical alternatives that address pain, wellness, and performance-related needs.
CEO Mr. Joshua S. Lev · 83 employees · United States · https://www.electrocore.com
